141 related articles for article (PubMed ID: 16314636)
1. Bexarotene and erlotinib for aerodigestive tract cancer.
Dragnev KH; Petty WJ; Shah S; Biddle A; Desai NB; Memoli V; Rigas JR; Dmitrovsky E
J Clin Oncol; 2005 Dec; 23(34):8757-64. PubMed ID: 16314636
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; Biddle A; Davis TH; Nugent WC; Memoli N; Hamilton M; Iwata KK; Rigas JR; Dmitrovsky E
Clin Cancer Res; 2004 Nov; 10(22):7547-54. PubMed ID: 15569985
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
4. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Dragnev KH; Ma T; Cyrus J; Galimberti F; Memoli V; Busch AM; Tsongalis GJ; Seltzer M; Johnstone D; Erkmen CP; Nugent W; Rigas JR; Liu X; Freemantle SJ; Kurie JM; Waxman S; Dmitrovsky E
Cancer Prev Res (Phila); 2011 Jun; 4(6):818-28. PubMed ID: 21636548
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
Govindan R; Crowley J; Schwartzberg L; Kennedy P; Williams C; Ekstrand B; Sandler A; Jaunakais D; Bolejack V; Ghalie R
J Clin Oncol; 2006 Oct; 24(30):4848-54. PubMed ID: 17050870
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
10. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA
Cancer; 2006 Sep; 107(5):1034-41. PubMed ID: 16878326
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
[TBL] [Abstract][Full Text] [Related]
17. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
[TBL] [Abstract][Full Text] [Related]
18. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
19. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
20. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
